1
|
Clinical Impact of Recipient-Derived Isoagglutinin Levels in ABO-Incompatible Hematopoietic Stem Cell Transplantation. J Clin Med 2023; 12:jcm12020458. [PMID: 36675387 PMCID: PMC9866227 DOI: 10.3390/jcm12020458] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 12/30/2022] [Accepted: 01/04/2023] [Indexed: 01/09/2023] Open
Abstract
ABO incompatibility is not considered a contraindication for hematopoietic stem cell transplantation (HSCT). We hypothesized that recipient-derived isoagglutinin (RDI) levels could play a critical role in clinical outcomes. In this study, we compared clinical outcomes such as survival, GVHD, infection, relapse, transfusion, and engraftment, among ABO-compatible patients (ABOc), ABO-incompatible patients (ABOi) with low RDI, and ABOi patients with high RDI. The ABOi with high RDI group was defined as recipients with more than 1:16 RDI levels. We analyzed 103 recipients (ABOc, 53; ABOi with low RDI, 36; ABOi with high RDI, 14). The ABOi with high RDI group showed a decreased 1-year survival and increased acute GVHD grade IV and RBC transfusion (p = 0.017, 0.027, and 0.032, respectively). The ABOi with high RDI group was an independent risk factor for increased death, RBC transfusion, and poor platelet (PLT) engraftment (odds ratio (OR) = 3.20, p = 0.01; OR = 8.28, p = 0.02; OR = 0.18, p = 0.03, respectively). The ABOi with high RDI group showed significantly delayed PLT engraftment. In conclusion, this is the first study underscoring high RDI levels as a marker predicting unfavorable outcomes in ABOi HSCT.
Collapse
|
2
|
Caliskan K, Can G. Determining the symptoms and coping methods of patients at home after hematopoietic stem cell transplantation. Support Care Cancer 2022; 30:5881-5890. [PMID: 35376995 DOI: 10.1007/s00520-022-07017-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Accepted: 03/25/2022] [Indexed: 11/12/2022]
Abstract
AIM This descriptive study was conducted to determine symptoms experienced at home in the early period by patients who received hematopoietic stem cell transplantation (HSCT), identify coping behaviors used by the patients in the management of symptoms and assess the quality of life of these patients. METHOD The study included 200 patients who had received HSCT at a private hospital in Kocaeli in Turkey between October 2017 and November 2018 and been discharged. The data of the study were collected by using a patient information and interview form developed by the researcher, the Memorial Symptom Assessment Scale and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. RESULTS The mean age of the patients was approximately 51, 39% (n = 78) of the patients were female, 61% (n = 122) were male, and the vast majority (82%) were married. The three most frequently experienced symptoms among the patients after being discharged were identified as pain (63%), weakness (48%), and loss of appetite (43%). It was found that the vast majority of the patients complied with coping behaviors reported in the literature, but these behaviors were partially effective. Clinical diagnosis, type of transplant, status of re-hospitalization of the being discharged, and number of problems experienced were identified as variables that were significantly effective on the treatment-related symptom experiences and many dimensions of the quality of life of the patients (p < 0.05). CONCLUSION It was determined that the patients who were included in this study experienced various symptoms on different levels and at different frequencies. Regarding the effectiveness of the approaches used by the patients in coping with the symptoms they experienced, it was determined that the approaches they used to cope with nausea-vomiting, fever and insomnia were effective, and those they used for weight loss and anxiety were ineffective.
Collapse
Affiliation(s)
- Kader Caliskan
- Anadolu Medical Center, Cumhuriyet Mahallesi, 2255 Sokak, No: 3 Gebze, 41400, Kocaeli, Turkey.
| | - Gulbeyaz Can
- Istanbul University - Cerrahpasa Florence Nightingale Nursing Faculty, Abide-i Hürriyet Cad, Caglayan 34403, Istanbul, Turkey
| |
Collapse
|
3
|
Nakagaki M, Gavin NC, Hayes T, Fichera R, Stewart C, Naumann L, Brennan J, Perry N, Foley E, Crofton E, Brown C, Leutenegger J, Kennedy GA. Implementation and evaluation of a nurse-allied health clinic for patients after haematopoietic stem cell transplantation. Support Care Cancer 2021; 30:647-657. [PMID: 34363493 DOI: 10.1007/s00520-021-06461-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Accepted: 07/21/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE Patients who undergo haematopoietic stem cell transplantation (HSCT) often have multiple health issues following hospital discharge. In many centres, outpatient follow-up is solely conducted by specialist physicians. We aimed to implement and describe the outcomes of a nurse-allied health multidisciplinary clinic. METHODS The clinic consisted of six disciplines-nursing, pharmacy, dietetics, physiotherapy, occupational therapy and social work. All allogeneic and high risk autologous HSCT patients were reviewed at 2 weeks after discharge and on day 100 post HSCT, with additional reviews as needed. Occasions of service, interventions, readmission data and physician satisfaction survey were collected prior to and after implementation. Additionally, patient feedback and quality of life survey (FACT-BMT) were collected during the first 6 months. RESULTS From July to December 2019, 57 patients were reviewed in the clinic (475 reviews, average 8.3 reviews per patient). Common interventions included the following: exercise programs by physiotherapist (n = 111), diet prescription (n = 103), counselling by social worker (n = 53), medication lists provision (n = 51), fatigue management (n = 43) and nurse education (n = 22). The clinic did not reduce patients' readmission rate; however, positive feedback from patients and physicians were reported. FACT-BMT results demonstrated that there are unmet needs, particularly fatigue management, sexual education and support, body images, back to work support and quality of life improvement. From discharge to day 100, there was no significant improvement in quality of life. CONCLUSIONS This clinic provides an innovative approach to patient-centred care in HSCT. It has been well received by patients who were supported by multidisciplinary interventions.
Collapse
Affiliation(s)
- Midori Nakagaki
- Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
| | - Nicole C Gavin
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.,School of Nursing, Queensland University of Technology, Brisbane, Australia
| | - Therese Hayes
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Rebecca Fichera
- Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Caroline Stewart
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Leonie Naumann
- Physiotherapy, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Justine Brennan
- Social Work, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Natasha Perry
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Emma Foley
- Occupational Therapy, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Erin Crofton
- Occupational Therapy, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Christie Brown
- Physiotherapy, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Jenni Leutenegger
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia
| | - Glen A Kennedy
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.,School of Medicine, The University of Queensland, Brisbane, Australia
| |
Collapse
|
4
|
Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients. Am J Clin Dermatol 2019; 20:55-73. [PMID: 30298481 DOI: 10.1007/s40257-018-0391-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Hematopoietic stem cell transplants (HSCTs) are used to treat a variety of conditions, including hematologic malignancies, bone marrow failure syndromes, and immunodeficiencies. Over 60,000 HSCTs are performed annually worldwide, and the numbers continue to increase. Indeed, as new conditioning regimens develop, more and more individuals, including those of older age, will be eligible for transplants. Nevertheless, although HSCTs are clearly a life-saving and necessary treatment for thousands of patients per year, there is still substantial morbidity and mortality associated with the procedure. Of note, skin eruptions in the post-HSCT period are frequent and often significantly reduce quality of life in recipients. Moreover, these cutaneous findings sometimes herald an underlying systemic condition, presenting possible opportunities for timelier intervention. Dermatologists therefore play a vital role in distinguishing life-threatening conditions from benign issues and prompting recognition of critical complications earlier in their course. This article aims to review the major dermatologic conditions occurring in the early post-HSCT period.
Collapse
|